PRODUCT INFORMATION

Zanamivir-$^{13}C,^{15}N_2$ (hydrate)

Item No. 30733

Formal Name: 5-(acetylamino)-4-[(amino-^{15}N-imino-^{15}N-methyl-^{13}C)amino]-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-ido-non-2-enonic acid, hydrate

MF: $C_{11}[^{13}C]H_{20}N_2[^{15}N]_2O_7 \bullet XH_2O$

FW: 335.3

Purity: ≥98%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Zanamivir-$^{13}C,^{15}N_2$ (hydrate) is supplied as a solid. A stock solution may be made by dissolving the zanamivir-$^{13}C,^{15}N_2$ (hydrate) in water. Zanamivir-$^{13}C,^{15}N_2$ (hydrate) is slightly soluble in water. We do not recommend storing the aqueous solution for more than one day.

Description

Zanamivir-$^{13}C,^{15}N_2$ is intended for use as an internal standard for the quantification of zanamivir (Item No. 15123) by GC- or LC-MS. Zanamivir is a sialic acid analog that inhibits neuraminidase release of newly replicated influenza virus particles.[1] It has been shown to selectively inhibit the growth of influenza A and B viruses in plaque reduction assays with IC_{50} values ranging from 5 to 14 nM and to directly inhibit influenza A and B virus neuraminidases with IC_{50} values ranging from 0.6 to 7.9 nM *in vitro*. Intranasal zanamivir administration at 0.4 mg/kg twice daily reduces mortality and viral titers in lung homogenates of mice infected with influenza.

Reference

1. Elliott, M. Zanamivir: From drug design to the clinic. *Philos. Trans. R. Soc. Lond. B Biol Sci.* **356(1416)**, 1885-1893 (2001).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM